Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Inclusion Criteria

• •Diagnosis
• •* Patients with first relapse or progression of rhabdomyosarcoma are eligible
• •* Patients with primary refractory disease are eligible
• •* Primary refractory disease is defined as first progression after receiving at least one course of cyclophosphamide or ifosfamide containing chemotherapy without prior demonstration of a radiographic response to chemotherapy (progression on irinotecan-containing chemotherapy without cyclophosphamide or ifosfamide containing chemotherapy will not be considered a first progression)
• •* Note: Patients without measurable or evaluable disease are eligible
• •Patients must have had a previous histological verification of rhabdomyosarcoma at original diagnosis
• •Patients must have a Karnofsky or Lansky performance status score of \>= 50%, corresponding to Eastern Cooperative Oncology Group (ECOG) categories of 0, 1, or 2; use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years of age
• •Patients must have a life expectancy of \>= 8 weeks
• •Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
• •Myelosuppressive chemotherapy: Must not have received within 3 weeks prior to entry onto this study (4 weeks if prior nitrosourea)
• •Biologic (anti-neoplastic agent):
• •* Patients may have received prior therapy with oral tyrosine kinase inhibitors or other similar agents; at least 7 days must have elapsed since the completion of therapy with a biologic agent and all toxicities must have resolved to \< grade 2 prior to enrollment
• •* 3 half-lives (or 6 weeks) must have elapsed since previous monoclonal antibody therapy prior to enrollment on this study
• •Myeloid growth factor: Must not have received within 1 week prior to entry onto this study
• •Radiation therapy (RT): At least 4 weeks must have elapsed between RT and study entry; previously radiated lesions cannot be used to assess response unless those sites are the sites of disease progression
• •Stem cell transplant (SCT): For autologous SCT, \>= 3 months must have elapsed; for allogeneic SCT, \>= 6 months must have elapsed and no evidence of active graft vs. host disease
• •Patients must have recovered from any surgical procedure before enrolling on this study
• •* Minor surgical procedures (e.g., biopsies involving core or fine-needle aspiration procedures, infusaport or Broviac line placement, paracentesis, or thoracocentesis) need to have fully healed and occurred \> 7 days prior to enrollment
• •* Patients who have had a major surgical procedure (such as laparotomy, thoracotomy, open biopsy, or resection of tumor) can only be enrolled on study \> 28 days from such procedure
• •Peripheral absolute neutrophil count (ANC) \>= 750/μL
• •Platelet count \>= 75,000/μL (transfusion independent, defined as without transfusion for \>= 1 week prior to enrollment)
• •Hemoglobin \>= 8.0 g/dL (may receive packed red blood cells \[PRBC\] transfusions)
• •Bone marrow disease involvement of tumor is allowed, however, peripheral blood count criteria must still be met
• •Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 OR a serum creatinine based on age/gender as follows:
• •* =\< 0.4 mg/dL (for patients aged 1 month to \< 6 months)
• •* =\< 0.5 mg/dL (for patients aged 6 months to \< 1 year)
• •* =\< 0.6 mg/dL (for patients aged 1 to \< 2 years)
• •* =\< 0.8 mg/dL (for patients aged 2 to \< 6 years)
• •* =\< 1 mg/dL (for patients aged 6 to \< 10 years)
• •* =\< 1.2 mg/dL (for patients aged 10 to \< 13 years)
• •* =\< 1.4 mg/dL (for female patients aged \>= 13 years)
• •* =\< 1.5 mg/dL (for male patients aged 13 to \< 16 years)
• •* =\< 1.7 mg/dL (for male patients aged \>= 16 years)
• •Urine protein level:
• •* Patients aged =\< 17 years: Urine protein to creatinine (UPC) ratio should be calculated; UPC ratio must be =\< 1 for patient to be eligible
• •* Patients aged \> 17 years: Urine protein should be screened by urine analysis; if protein is 2+ or higher, 24-hour urine protein must be obtained and the level must be \< 1,000 mg for patient enrollment
• •Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age
• •Shortening fraction of \>= 27% by echocardiogram or ejection fraction of \>= 50% by radionuclide angiogram